TMO Thermo Fisher Scientific

XNYS Up Alert

Health Care

· How we analyze

About the company

Thermo Fisher Scientific is a major US provider for labs and pharmaceutical research. It supplies analytical instruments, lab supplies and reagents and, as a service provider, takes over parts of drug development and manufacturing. Customers are pharmaceutical companies, labs and hospitals worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Other measuring instruments · Waltham, USA

Thermo Fisher Scientific supplies pharmaceutical companies, hospitals, diagnostic labs, universities, research institutes, government agencies and industry. The life sciences segment supplies reagents, instruments and consumables for biological and medical research and bioproduction. The analytical instruments range from chromatography and mass spectrometry to electron microscopy, also for semiconductor customers. For diagnostics there are test kits, reagents, culture media and instruments for hospitals, labs and food testing. Another segment supplies lab products and takes over outsourced development, manufacturing and clinical trials for pharmaceutical companies. Sales run through its own field sales force, customer service, e-commerce and third-party distributors.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Thermo Fisher Scientific

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +1.6%
  • 7 days +0.8%
  • 30 days +1.5%
  • 1 year +19.6%
Day range (last trading day)
−1.5%Price at 95% of the range+0.1%
52-week range
−36.4%Price at 92% of the range+3.1%
Distance from the all-time high
−3.0%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:TMO

Save zone

With a free account: save the buy zone shown for yourself (stop and targets from Watcher). It stays visible even if the zone changes later. Log in · Sign up

Fundamental analysis

Thermo Fisher Scientific · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 26, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+6.7% per year), more slowly than the sector median.
  • Light yellow: Net income (total) grew over 5 years (+1.0% per year), more slowly than the sector median; per share +2.1% per year.
  • Light green: Net margin 15.0%, above the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 7 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 18.3B USD · Net income not available · Net margin not available
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 20.9B USD · Net income not available · Net margin not available
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 24.4B USD · Net income not available · Net margin not available
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 25.5B USD · Net income 3.7B USD · Net margin 14.5%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 32.2B USD · Net income 6.4B USD · Net margin 19.8%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 39.2B USD · Net income 7.7B USD · Net margin 19.7%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 44.9B USD · Net income 7.0B USD · Net margin 15.5%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 42.9B USD · Net income 6.0B USD · Net margin 14.0%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 42.9B USD · Net income 6.3B USD · Net margin 14.8%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 44.6B USD · Net income 6.7B USD · Net margin 15.0%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 44.6B USD · Net income 6.7B USD · Net margin 15.0%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+6.7% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 6.7% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light yellow: below sector

+1.0% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +2.1% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 1.0% per year on average, but more slowly than the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

15.0% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 15.05 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 19.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.80 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 0.80 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

10% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.10 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

7 of 7 fiscal years with a profit

What does this mean? In 7 of the last 7 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
44.6B USD
Revenue vs. prior year
+3.9%
Net income (FY)
6.7B USD
Net income vs. prior year
+5.8%
EPS (FY)
17.74 USD
13F funds with a position
3 of 9
Funds vs. prior quarter
+1
Shares held vs. prior quarter
+0.3%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Jun 27, 2026 (filed Jul 31, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 44.6B6.7B 15.0% 17.74 1.72 10%
2024Dec 31, 2024 42.9B6.3B 14.8% 16.53 1.56 9%
2023Dec 31, 2023 42.9B6.0B 14.0% 15.45 1.40 9%
2022Dec 31, 2022 44.9B7.0B 15.5% 17.63 1.20 7%
2021Dec 31, 2021 39.2B7.7B 19.7% 19.46 1.04 5%
2020Dec 31, 2020 32.2B6.4B 19.8% 15.96 0.88 6%
2019Dec 31, 2019 25.5B3.7B 14.5% 9.17 0.76 8%
2018Dec 31, 2018 24.4B– – 7.24 0.68 9%
2017Dec 31, 2017 20.9B– – 5.59 0.60 11%
2016Dec 31, 2016 18.3B– – 5.09 0.60 12%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 27, 2026 12.0B1.7B 14.5% 4.68 0.47 10%
Q1/26Mar 28, 2026 11.0B1.7B 15.0% 4.43 0.47 11%
Q4/25*Dec 31, 2025 12.2B2.0B 16.1% – 0.43 –
Q3/25Sep 27, 2025 11.1B1.6B 14.5% 4.27 0.43 10%
Q2/25Jun 28, 2025 10.9B1.6B 14.9% 4.28 0.43 10%
Q1/25Mar 29, 2025 10.4B1.5B 14.5% 3.98 0.43 11%
Q4/24*Dec 31, 2024 11.4B1.8B 16.1% – 0.39 –
Q3/24Sep 28, 2024 10.6B1.6B 15.4% 4.25 0.39 9%
Q2/24Jun 29, 2024 10.5B1.5B 14.7% 4.04 0.39 10%
Q1/24Mar 30, 2024 10.3B1.3B 12.9% 3.46 0.39 11%
Q4/23*Dec 31, 2023 10.9B– – – 0.35 –
Q3/23Sep 30, 2023 10.6B1.7B 16.0% 4.42 0.35 8%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $61.6M5 people −$61.6M
6 months $00 people $61.7M5 people −$61.7M
12 months $00 people $148.1M7 people −$148.1M

Latest transactions

  • Aug 31, 2026 Pettiti Gianluca Officer Open-market sale · 10b5-1 plan 3,733 shares · $2.3M · SEC
  • Aug 31, 2026 Pettiti Gianluca Officer Open-market sale · 10b5-1 plan 400 shares · $245.8K · SEC
  • Aug 24, 2026 Casper Marc N Chief executive (CEO), Director Open-market sale · 10b5-1 plan 62 shares · $39.0K · SEC
  • Aug 24, 2026 Casper Marc N Chief executive (CEO), Director Open-market sale · 10b5-1 plan 79 shares · $49.6K · SEC
  • Aug 24, 2026 Casper Marc N Chief executive (CEO), Director Open-market sale · 10b5-1 plan 33 shares · $20.7K · SEC
  • Aug 24, 2026 Casper Marc N Chief executive (CEO), Director Open-market sale · 10b5-1 plan 101 shares · $63.2K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +100

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+20
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)32.0
Rel. strength 60 d+17.2%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on TMO yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: TMO

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close